Peter Kuebler

1.4k total citations
32 papers, 995 citations indexed

About

Peter Kuebler is a scholar working on Immunology, Hematology and Virology. According to data from OpenAlex, Peter Kuebler has authored 32 papers receiving a total of 995 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 10 papers in Hematology and 8 papers in Virology. Recurrent topics in Peter Kuebler's work include Immune Cell Function and Interaction (9 papers), Hemophilia Treatment and Research (9 papers) and HIV Research and Treatment (8 papers). Peter Kuebler is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Hemophilia Treatment and Research (9 papers) and HIV Research and Treatment (8 papers). Peter Kuebler collaborates with scholars based in United States, Switzerland and United Kingdom. Peter Kuebler's co-authors include Douglas F. Nixon, Amita Joshi, Lisa Tuomi, Nelson L. ‘Shasha’ Jumbe, Lu Xu, Tong Lu, Lisa A. Damico‐Beyer, Steve Eppler, Jianfeng Lü and Gabriel M. Ortiz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Peter Kuebler

31 papers receiving 947 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Kuebler United States 15 418 255 250 176 175 32 995
Daniele Accapezzato Italy 19 987 2.4× 134 0.5× 251 1.0× 160 0.9× 77 0.4× 47 1.6k
A McMichael United Kingdom 18 751 1.8× 177 0.7× 235 0.9× 79 0.4× 172 1.0× 31 1.3k
Ai Kariyone Japan 16 696 1.7× 22 0.1× 171 0.7× 240 1.4× 59 0.3× 37 1.0k
Vittorio Francavilla Italy 16 878 2.1× 203 0.8× 157 0.6× 105 0.6× 40 0.2× 31 1.3k
Geraldine M. O’Connor United States 19 1.2k 2.9× 115 0.5× 136 0.5× 67 0.4× 27 0.2× 31 1.4k
J C Gluckman France 17 380 0.9× 328 1.3× 137 0.5× 162 0.9× 64 0.4× 37 811
Nobuyuki Takayama Japan 15 135 0.3× 34 0.1× 229 0.9× 84 0.5× 19 0.1× 55 753
Maud Milder France 9 865 2.1× 38 0.1× 233 0.9× 48 0.3× 25 0.1× 14 1.4k
John Zhong United States 10 574 1.4× 64 0.3× 262 1.0× 116 0.7× 433 2.5× 12 1.1k
Louise Y.C. Takeshita United Kingdom 7 690 1.7× 43 0.2× 305 1.2× 151 0.9× 95 0.5× 9 1.1k

Countries citing papers authored by Peter Kuebler

Since Specialization
Citations

This map shows the geographic impact of Peter Kuebler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kuebler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kuebler more than expected).

Fields of papers citing papers by Peter Kuebler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kuebler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kuebler. The network helps show where Peter Kuebler may publish in the future.

Co-authorship network of co-authors of Peter Kuebler

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kuebler. A scholar is included among the top collaborators of Peter Kuebler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kuebler. Peter Kuebler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nissen, Francis, et al.. (2021). Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. Journal of Comparative Effectiveness Research. 10(18). 1323–1336. 7 indexed citations
2.
Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations
3.
Peyvandi, Flora, Johnny Mahlangu, Steven W. Pipe, et al.. (2020). Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis. 19. 32–41. 14 indexed citations
4.
Pipe, Steven W., Rebecca Kruse‐Jarres, Johnny Mahlangu, et al.. (2020). Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis. 19. 21–31. 9 indexed citations
5.
Levy, Gallia G., et al.. (2019). Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. Journal of Thrombosis and Haemostasis. 17(9). 1470–1477. 49 indexed citations
6.
Kuebler, Peter, Brian I. Shaw, Megha Mehrotra, et al.. (2015). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 72(2). 184–188. 1 indexed citations
7.
Kuebler, Peter, Megha Mehrotra, Brian I. Shaw, et al.. (2015). Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+T-Cell Activation. The Journal of Infectious Diseases. 213(4). 569–573. 9 indexed citations
8.
Zhang, Yi Xin, Zhenling Yao, Peter Kuebler, et al.. (2014). Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema. Ophthalmology. 121(11). 2237–2246. 29 indexed citations
9.
Xu, Lu, Tong Lu, Lisa Tuomi, et al.. (2013). Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach. Investigative Ophthalmology & Visual Science. 54(3). 1616–1616. 161 indexed citations
10.
Chen, Haoyan, Henri‐Alexandre Michaud, Genki Hayashi, et al.. (2012). Protective Effect of Human Endogenous Retrovirus K dUTPase Variants on Psoriasis Susceptibility. Journal of Investigative Dermatology. 132(7). 1833–1840. 20 indexed citations
11.
Chen, Haoyan, Genki Hayashi, Alexander Dilthey, et al.. (2012). Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genetics. 8(2). e1002514–e1002514. 55 indexed citations
12.
Willberg, Christian B., Peter Kuebler, Jacob Abadi, et al.. (2011). Immunodominance of HIV-1 Specific CD8+ T-Cell Responses Is Related to Disease Progression Rate in Vertically Infected Adolescents. PLoS ONE. 6(7). e21135–e21135. 6 indexed citations
13.
Yao, Zhenling, et al.. (2009). Prevention of Laser Photocoagulation Induced Choroidal Neovascularization Lesions by Intravitreal Doses of Ranibizumab in Cynomolgus Monkeys. Investigative Ophthalmology & Visual Science. 50(13). 785–785. 2 indexed citations
14.
Joshi, Amita, Robert J. Bauer, Peter Kuebler, et al.. (2006). An Overview of the Pharmacokinetics and Pharmacodynamics of Efalizumab: A Monoclonal Antibody Approved for Use in Psoriasis. The Journal of Clinical Pharmacology. 46(1). 10–20. 52 indexed citations
15.
Rakoff-Nahoum, Seth, Peter Kuebler, Jonas J. Heymann, et al.. (2006). Detection of T Lymphocytes Specific for Human Endogenous Retrovirus K (HERV-K) in Patients with Seminoma. AIDS Research and Human Retroviruses. 22(1). 52–56. 50 indexed citations
16.
Mortensen, Deborah L., Patricia A. Walicke, Xiaolin Wang, et al.. (2005). Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology. 45(3). 286–298. 47 indexed citations
17.
Ortiz, Gabriel M., Douglas F. Nixon, Alexandra Trkola, et al.. (1999). HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. Journal of Clinical Investigation. 104(6). R13–R18. 198 indexed citations
18.
Nixon, Douglas F., Catarina E. Hioe, Peter Kuebler, et al.. (1996). Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine. 14(16). 1523–1530. 114 indexed citations
19.
Hioe, Catarina E., Manmohan Singh, Peter Kuebler, et al.. (1996). Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine. 14(5). 412–418. 26 indexed citations
20.
Kuebler, Peter. (1996). Cytotoxic T cell induction with ratchet peptide libraries. Vaccine. 14(17-18). 1664–1670. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniele Accapezzato Breakdown of academic impact, for papers by A McMichael Breakdown of academic impact, for papers by Ai Kariyone Breakdown of academic impact, for papers by Vittorio Francavilla Breakdown of academic impact, for papers by Geraldine M. O’Connor Breakdown of academic impact, for papers by J C Gluckman Breakdown of academic impact, for papers by Nobuyuki Takayama Breakdown of academic impact, for papers by Maud Milder Breakdown of academic impact, for papers by John Zhong Breakdown of academic impact, for papers by Louise Y.C. Takeshita
Rankless by CCL
2026